FULCRUM THERAPEUTICS, INC. Stock-Based Compensation
FULCRUM THERAPEUTICS, INC. (FULC) reported Stock-Based Compensation of $3.27 million for the 3-month period ending 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-09-02
- FULCRUM THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.27M, a 13.77% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $3.86M, a 21.88% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $3.07M, a 23.78% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.36M, a 11.97% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $14.80M, a 10.88% increase from fiscal 2022.
- FULCRUM THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $13.35M, a 20.60% increase from fiscal 2021.
- FULCRUM THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2021 was $11.07M, a 50.61% increase from fiscal 2020.
- FULCRUM THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2020 was $7.35M, a 74.01% increase from fiscal 2019.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.27M S-4 · filed 2026-09-02 | $7.13M S-4 · filed 2026-09-02 | $10.20M derived: sum of 3 quarters · filed 2026-09-02 | $13.56M derived: sum of 4 quarters · filed 2026-09-02 |
| 2026-03-31 | $3.86M 10-Q · filed 2026-04-27 | $6.93M derived: sum of 2 quarters · filed 2026-09-02 | $10.29M derived: sum of 3 quarters · filed 2026-09-02 | $13.16M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-12-31 | $3.07M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $6.43M derived: sum of 2 quarters · filed 2026-09-02 | $9.30M derived: sum of 3 quarters · filed 2026-09-02 | $12.47M S-4 · filed 2026-09-02 |
| 2025-09-30 | $3.36M 10-Q · filed 2025-10-29 | $6.24M derived: sum of 2 quarters · filed 2026-09-02 | $9.40M 10-Q · filed 2025-10-29 | $11.88M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-06-30 | $2.88M S-4 · filed 2026-09-02 | $6.04M S-4 · filed 2026-09-02 | $8.52M derived: sum of 3 quarters · filed 2026-09-02 | $12.34M derived: sum of 4 quarters · filed 2026-09-02 |
| 2025-03-31 | $3.17M 10-Q · filed 2026-04-27 | $5.64M derived: sum of 2 quarters · filed 2026-09-02 | $9.46M derived: sum of 3 quarters · filed 2026-09-02 | $13.80M derived: sum of 4 quarters · filed 2026-09-02 |
| 2024-12-31 | $2.48M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-02 | $6.29M derived: sum of 2 quarters · filed 2026-09-02 | $10.64M derived: sum of 3 quarters · filed 2026-09-02 | $14.55M S-4 · filed 2026-09-02 |
| 2024-09-30 | $3.82M 10-Q · filed 2025-10-29 | $8.16M derived: sum of 2 quarters · filed 2025-10-29 | $12.08M 10-Q · filed 2025-10-29 | $15.53M derived: sum of 4 quarters · filed 2025-10-29 |
| 2024-06-30 | $4.34M 10-Q · filed 2025-07-29 | $8.26M 10-Q · filed 2025-07-29 | $11.71M derived: sum of 3 quarters · filed 2025-07-29 | $15.45M derived: sum of 4 quarters · filed 2025-07-29 |
| 2024-03-31 | $3.92M 10-Q · filed 2025-05-01 | $7.37M derived: sum of 2 quarters · filed 2025-05-01 | $11.10M derived: sum of 3 quarters · filed 2025-05-01 | $14.46M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $3.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $7.19M derived: sum of 2 quarters · filed 2025-02-25 | $10.55M derived: sum of 3 quarters · filed 2025-02-25 | $14.80M 10-K · filed 2025-02-25 |
| 2023-09-30 | $3.74M 10-Q · filed 2024-11-13 | $7.10M derived: sum of 2 quarters · filed 2024-11-13 | $11.35M 10-Q · filed 2024-11-13 | $14.62M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $3.36M 10-Q · filed 2024-07-31 | $7.62M 10-Q · filed 2024-07-31 | $10.89M derived: sum of 3 quarters · filed 2024-07-31 | $14.24M derived: sum of 4 quarters · filed 2024-07-31 |
| 2023-03-31 | $4.25M 10-Q · filed 2024-05-13 | $7.52M derived: sum of 2 quarters · filed 2024-05-13 | $10.88M derived: sum of 3 quarters · filed 2024-05-13 | $13.76M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $3.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $6.62M derived: sum of 2 quarters · filed 2024-02-27 | $9.50M derived: sum of 3 quarters · filed 2024-02-27 | $13.35M 10-K · filed 2024-02-27 |
| 2022-09-30 | $3.35M 10-Q · filed 2023-11-07 | $6.23M derived: sum of 2 quarters · filed 2023-11-07 | $10.08M 10-Q · filed 2023-11-07 | $13.87M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $2.88M 10-Q · filed 2023-08-03 | $6.73M 10-Q · filed 2023-08-03 | $10.52M derived: sum of 3 quarters · filed 2023-08-03 | $13.18M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $3.85M 10-Q · filed 2023-05-15 | $7.64M derived: sum of 2 quarters · filed 2023-06-26 | $10.30M derived: sum of 3 quarters · filed 2023-06-26 | $12.84M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-12-31 | $3.79M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $6.45M derived: sum of 2 quarters · filed 2023-06-26 | $9.00M derived: sum of 3 quarters · filed 2023-06-26 | $11.07M 10-K/A · filed 2023-06-26 |
| 2021-09-30 | $2.66M 10-Q · filed 2022-11-08 | $5.20M derived: sum of 2 quarters · filed 2022-11-08 | $7.28M 10-Q · filed 2022-11-08 | $8.95M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-06-30 | $2.55M 10-Q · filed 2022-08-11 | $4.62M 10-Q · filed 2022-08-11 | $6.30M derived: sum of 3 quarters · filed 2023-06-26 | $8.07M derived: sum of 4 quarters · filed 2023-06-26 |
| 2021-03-31 | $2.07M 10-Q · filed 2022-05-09 | $3.75M derived: sum of 2 quarters · filed 2023-06-26 | $5.53M derived: sum of 3 quarters · filed 2023-06-26 | $7.73M derived: sum of 4 quarters · filed 2023-06-26 |
| 2020-12-31 | $1.68M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-26 | $3.45M derived: sum of 2 quarters · filed 2023-06-26 | $5.66M derived: sum of 3 quarters · filed 2023-06-26 | $7.35M 10-K/A · filed 2023-06-26 |
| 2020-09-30 | $1.78M 10-Q · filed 2021-11-04 | $3.98M derived: sum of 2 quarters · filed 2021-11-04 | $5.67M 10-Q · filed 2021-11-04 | $6.95M derived: sum of 4 quarters · filed 2023-06-23 |
| 2020-06-30 | $2.20M 10-Q · filed 2021-08-10 | $3.90M 10-Q · filed 2021-08-10 | $5.17M derived: sum of 3 quarters · filed 2023-06-23 | $6.35M derived: sum of 4 quarters · filed 2023-06-23 |
| 2020-03-31 | $1.69M 10-Q · filed 2021-05-06 | $2.97M derived: sum of 2 quarters · filed 2023-06-23 | $4.15M derived: sum of 3 quarters · filed 2023-06-23 | $5.10M derived: sum of 4 quarters · filed 2023-06-23 |
| 2019-12-31 | $1.27M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-06-23 | $2.45M derived: sum of 2 quarters · filed 2023-06-23 | $3.40M derived: sum of 3 quarters · filed 2023-06-23 | $4.22M 10-K/A · filed 2023-06-23 |
| 2019-09-30 | $1.18M 10-Q · filed 2020-11-10 | $2.13M derived: sum of 2 quarters · filed 2020-11-10 | $2.95M 10-Q · filed 2020-11-10 | $3.71M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | $950.00K 10-Q · filed 2020-08-11 | $1.77M 10-Q · filed 2020-08-11 | $2.53M derived: sum of 3 quarters · filed 2020-08-11 | $3.04M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $821.00K 10-Q · filed 2020-05-13 | $1.58M derived: sum of 2 quarters · filed 2020-05-13 | $2.09M derived: sum of 3 quarters · filed 2020-05-13 | $2.55M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | $762.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $1.27M derived: sum of 2 quarters · filed 2020-03-05 | $1.73M derived: sum of 3 quarters · filed 2020-03-05 | $2.16M 10-K · filed 2020-03-05 |
| 2018-09-30 | $506.00K 10-Q · filed 2019-11-14 | $968.00K derived: sum of 2 quarters · filed 2019-11-14 | $1.40M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $462.00K 10-Q · filed 2019-08-26 | $891.00K 10-Q · filed 2019-08-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |